Molecular Factors in Carcinoma Ex Pleomorphic Adenoma: Systematic Review and Meta-Analysis.

Autor: Key S; Faculty of Medicine and Health, University of Sydney, Westmead, New South Wales, Australia.; St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia., Chia C; St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Hasan Z; Faculty of Medicine and Health, University of Sydney, Westmead, New South Wales, Australia.; Department of Otolaryngology - Head and Neck Surgery, Westmead Hospital, New South Wales, Westmead, New South Wales, Australia.; Department of Otolaryngology - Head and Neck Surgery, John Hunter Hospital, Sydney, New South Wales, Australia., Sundaresan P; Faculty of Medicine and Health, University of Sydney, Westmead, New South Wales, Australia.; Department of Radiation Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia., Riffat F; Faculty of Medicine and Health, University of Sydney, Westmead, New South Wales, Australia.; Department of Otolaryngology - Head and Neck Surgery, Westmead Hospital, New South Wales, Westmead, New South Wales, Australia.; Macquarie University Hospital, Macquarie University, New South Wales, Australia., Dwivedi RC; Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia.; Department of Otolaryngology - Head and Neck Surgery, University College London Hospitals NHS Foundation Trust, London, UK.; Division of Surgery and Interventional Science, University College London, London, UK.
Jazyk: angličtina
Zdroj: The Laryngoscope [Laryngoscope] 2024 Mar; Vol. 134 (3), pp. 1042-1053. Date of Electronic Publication: 2023 Aug 23.
DOI: 10.1002/lary.30993
Abstrakt: Objective: Carcinoma ex pleomorphic adenoma (CXPA) is a rare malignant salivary gland tumor. Although multiple reviews have been published on salivary gland malignancies, it has been a decade since the last dedicated systematic review pertaining to CXPA alone was published. This study examines molecular factors in CXPA diagnosis.
Data Sources: MEDLINE, CINAHL, Embase, Scopus, Web of Science (BIOSIS), Cochrane CENTRAL, Health Collection (Informit), OpenDOAR, and GreyNet International.
Review Methods: Systematic review and meta-analysis from inception to October 31, 2022 for all English language studies pertaining to "carcinoma ex pleomorphic adenoma." Predicted incidence of each biomarker was calculated with meta-analysis. Comparison against pleomorphic adenoma (PA) and salivary duct carcinoma (SDC) when reported within the same study are performed. Risk of bias performed with JBI tool for prevalence studies.
Results: Of 19151 unique studies undergoing abstract screening, 55 studies (n = 1322 patients) underwent data analysis. Biomarkers with >3 studies were p53, HER2, AR, EGFR, PLAG1, ERBB, ER, PR, HMGA2, p16, p63, a-SMA, RAS, PTEN, PDL1, BRAF, PIK3CA, and c-kit. Highest incidence was seen in AR, EGFR, p16, and p53. Significant differences were demonstrated compared with PA and SDC. There was high heterogeneity and overall high risk of bias within studies.
Conclusion: Molecular factors are an area of interest in the diagnosis of CXPA. Our study results support examining CXPA as a discrete cohort in future targeted therapy trials. Laryngoscope, 134:1042-1053, 2024.
(© 2023 The American Laryngological, Rhinological and Otological Society, Inc.)
Databáze: MEDLINE
Externí odkaz: